Table 4 Prescription by pharmacological group and type of HF.

2020

De novo HF without previous heart disease

De novo with previous heart disease

Non-de novo

ACEI/ARB

ARNI

RAASI

Bb

MRA

SGLT2i

ACEI/ARB

ARNI

RAASI

Bb

MRA

SGLT2i

ACEI/ARB

ARNI

RAASI

Bb

MRA

SGLT2i

Admission

0

0

0

0

0

0

14(70.0)

0

14(70.0)

11(55.0)

3(15.0)

2(10.0)

27(30.0)

23(25.6)

49(54.4)

74(82.2)

43(47.8)

15(16.7)

Discharge

9(36.0)

9(36.0)

18(72.0)

14(56.0)

13(52.0)

2(8.0)

14(70.0)

4(20.0)

18(90.0)

18(90.0)

11(55.0)

5(25.0)

24(26.7)

37(41.1)

60(66.7)

71(78.9)

50(55.6)

20(22.2)

P

-

-

-

-

-

-

1

-

0.219

0.016

0.008

0.250

0.648

0.007

0.052

0.607

0.167

0.063

Difference % (CI95%)

36.0(15.2/56.8)

36.0(15.2/56.8)

72.0(52.4/91.6)

56.0(34.5/77.5)

52.0(30.4/73.6)

8.0(1.0/26.0)

0.0(-31.3/31.3)

20.0(5.7/43.7)

20.0(-8.5/29.7)

40.0(11.1/47.8)

40.0(7.8/48.8)

15.0(-17.8/27.2)

-3.3(-12.6/7.0)

15.5(5.4/25.7)

12.2(1.2/23.2)

-3.3(-11.2/5.9)

7.8(-2.8/15.8)

5.5(-1.5/8.5)

2021

ACEI/ARB

ARNI

RAASI

Bb

MRA

SGLT2i

ACEI/ARB

ARNI

RAASI

Bb

MRA

SGLT2i

ACEI/ARB

ARNI

RAASI

Bb

MRA

SGLT2i

Admission

0

0

0

0

0

0

35(76.1)

1(2.2)

36(78.3)

14(30.4)

1(2.2)

6(13.0)

63(37.1)

48(28.2)

111(65.3)

136(80.0)

98(57.6)

61(35.9)

Discharge

21(46.7)

15(33.3)

36(80.0)

38(84.4)

33(73.3)

15(33.3)

22(47.8)

15(32.6)

37(80.4)

40(87.0)

20(43.5)

17(37.0)

43(25.3)

71(41.8)

114(67.1)

142(83.5)

117(68.8)

80(47.1)

P

-

-

-

-

-

-

0.007

< 0.001

0.999

< 0.001

< 0.001

0.001

0.002

< 0.001

0.690

0.362

0.001

< 0.001

Difference % (CI95%)

46.7(31.0/62.4)

33.3(18.4/48.2)

80.0(67.2/92.8)

84.4(72.7/96.1)

73.3(59.3/87.3)

33.3(18.4/48.2)

-28.3(-46.0/-10.5)

30.4(11.5/31.8)

2.1(-12.7/15.9)

56.6(40.8/72.3)

41.3(25.9/56.8)

24.0(8.7/28.0)

-11.8(-18.8/-4.7)

13.5(7.2/19.8)

1.8(-4.0/7.5)

3.5(-2.8/9.8)

11.2(5.2/17.2)

11.2(5.4/16.9)

2022

ACEI/ARB

ARNI

RAASI

Bb

MRA

SGLT2i

ACEI/ARB

ARNI

RAASI

Bb

MRA

SGLT2i

ACEI/ARB

ARNI

RAASI

Bb

MRA

SGLT2i

Admission

0

0

0

0

0

0

30(73.2)

0

30(73.2)

15(36.6)

2(4.9)

9(22.0)

39(30.7)

40(31.5)

79(62.2)

88(69.3)

69(54.3)

69(54.3)

Discharge

12(31.6)

14(36.8)

26(68.4)

27(71.1)

26(68.4)

24(63.2)

17(41.5)

18(43.9)

35(85.4)

36(87.8)

29(70.7)

26(63.4)

31(24.4)

48(37.8)

79(62.2)

92(72.4)

81(63.8)

95(74.8)

P

-

-

-

-

-

-

0.004

-

0.227

< 0.001

< 0.001

< 0.001

0.096

0.115

1

0.424

0.004

< 0.001

Difference % (CI95%)

31.6(15.5/47.7)

36.8(20.2/53.5)

68.4(52.3/84.5)

71.1(55.3/86.8)

68.4(52.3/84.5)

63.2(46.5/79.8)

-31.7(-43.2/-9.7)

43.9(27.5/60.3)

12.2(-5.9/23.6)

51.2(39.2/63.1)

65.8(47.9/80.5)

41.4(25.6/57.2)

-6.3(-11.4/1.0)

6.3(-0.5/13.1)

0.0(-6.8/6.8)

3.1(-3.3/8.2)

9.5(2.9/12.2)

20.5(13.1/27.8)

2020–2022

ACEI/ARB

ARNI

RAASI

Bb

MRA

SGLT2i

ACEI/ARB

ARNI

RAASI

Bb

MRA

SGLT2i

ACEI/ARB

ARNI

RAASI

Bb

MRA

SGLT2i

Admission

0

0

0

0

0

0

79(73.8)

1(0.9)

80(74.8)

40(37.4)

6(5.6)

17(15.9)

129(33.3)

111(28.7)

239(61.8)

298(77.0)

210(54.3)

145(37.5)

Discharge

42(38.9)

38(35.2)

80(74.1)

79(73.1)

72(66.7)

41(38.0)

53(49.5)

37(34.6)

90(84.1)

94(87.9)

60(56.1)

48(44.9)

98(25.3)

156(40.3)

253(65.4)

305(78.8)

248(64.1)

195(50.4)

P

-

-

-

-

-

-

< 0.001

< 0.001

0.087

< 0.001

< 0.001

< 0.001

0.001

< 0.001

0.120

0.435

< 0.001

< 0.001

Difference % (CI95%)

38.9(29.2/48.5)

35.2(25.7–44.7)

74.1(65.3/82.8)

73.1(64.3/82.0)

66.7(57.3/76.0)

38.0(28.3/47.6)

-24.3(-36.4/-12.2)

33.7(24.8/42.7)

9.3(-0.2/18.9)

50.5(40.6/60.4)

50.5(40.6/60.3)

29.0(20.1/37.9)

-8.0(-12.4/-3.6)

11.6(7.3/15.9)

3.6(-0.6/7.8)

1.8(-2.1/5.7)

9.8(5.9/13.8)

12.9(9.2/16.6)